This company has been marked as potentially delisted and may not be actively trading. Vital Therapies (VTL) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock VTL vs. BIOA, CYBN, VIRI, WHWK, OSTX, ELYM, ATNM, NBRV, PYRGF, and AADIShould you be buying Vital Therapies stock or one of its competitors? The main competitors of Vital Therapies include BioAge Labs (BIOA), Cybin (CYBN), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), OS Therapies (OSTX), Eliem Therapeutics (ELYM), Actinium Pharmaceuticals (ATNM), Nabriva Therapeutics (NBRV), PyroGenesis Canada (PYRGF), and Aadi Bioscience (AADI). Vital Therapies vs. Its Competitors BioAge Labs Cybin Virios Therapeutics Whitehawk Therapeutics OS Therapies Eliem Therapeutics Actinium Pharmaceuticals Nabriva Therapeutics PyroGenesis Canada Aadi Bioscience Vital Therapies (NASDAQ:VTL) and BioAge Labs (NASDAQ:BIOA) are both small-cap pharmaceutical preparations industry companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership. Do institutionals & insiders have more ownership in VTL or BIOA? 15.5% of Vital Therapies shares are owned by institutional investors. 33.9% of Vital Therapies shares are owned by insiders. Comparatively, 20.8% of BioAge Labs shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is VTL or BIOA more profitable? BioAge Labs' return on equity of -25.39% beat Vital Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Vital TherapiesN/A -235.33% -182.35% BioAge Labs N/A -25.39%-23.22% Which has preferable valuation & earnings, VTL or BIOA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVital TherapiesN/AN/A-$41.47MN/AN/ABioAge LabsN/AN/A-$71.11MN/AN/A Does the media favor VTL or BIOA? In the previous week, BioAge Labs had 2 more articles in the media than Vital Therapies. MarketBeat recorded 2 mentions for BioAge Labs and 0 mentions for Vital Therapies. Vital Therapies' average media sentiment score of 0.00 equaled BioAge Labs'average media sentiment score. Company Overall Sentiment Vital Therapies Neutral BioAge Labs Neutral SummaryVital Therapies and BioAge Labs tied by winning 3 of the 6 factors compared between the two stocks. Get Vital Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for VTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTL vs. The Competition Export to ExcelMetricVital TherapiesPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$40.25M$837.08M$5.83B$9.78BDividend YieldN/A4.84%4.40%4.05%P/E RatioN/A1.1622.8124.74Price / SalesN/A26.35473.17122.93Price / CashN/A19.5638.0259.36Price / Book3.286.649.536.60Net Income-$41.47M-$4.94M$3.26B$265.65M Vital Therapies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTLVital TherapiesN/A$0.95+0.5%N/A-37.8%$40.25MN/A0.0010BIOABioAge LabsN/A$4.42-2.2%N/AN/A$162.04MN/A0.00N/ACYBNCybin2.4338 of 5 stars$6.59-4.8%$85.00+1,189.8%N/A$155.46MN/A-1.5050News CoverageAnalyst RevisionVIRIVirios TherapeuticsN/A$5.30+7.5%$5.00-5.7%+2,256.9%$102.07MN/A-19.635Gap UpWHWKWhitehawk TherapeuticsN/A$1.65+2.5%N/AN/A$75.88M$25.98M-27.5040High Trading VolumeOSTXOS Therapies2.1688 of 5 stars$2.15-1.4%$18.00+737.2%-39.8%$67.99MN/A-2.50N/AAnalyst ForecastGap UpELYMEliem TherapeuticsN/A$2.11+11.1%N/A-62.3%$62.78MN/A-3.989News CoveragePositive NewsHigh Trading VolumeATNMActinium Pharmaceuticals2.9839 of 5 stars$1.65-3.5%$4.50+172.7%-14.1%$51.47MN/A-1.1930Positive NewsShort Interest ↓NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070PYRGFPyroGenesis CanadaN/A$0.23-5.6%N/A-63.8%$42.89M$9.14M-3.8190Gap UpHigh Trading VolumeAADIAadi Bioscience0.444 of 5 stars$1.61+0.6%$1.67+3.5%+6.5%$39.76M$25.07M-0.7140 Related Companies and Tools Related Companies BIOA Competitors CYBN Competitors VIRI Competitors WHWK Competitors OSTX Competitors ELYM Competitors ATNM Competitors NBRV Competitors PYRGF Competitors AADI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTL) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vital Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vital Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access